Gsa Capital Partners LLP Precision Biosciences Inc Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.91 $11,952 - $20,916	-22,985 Reduced 4.66%	469,990 $249,000
Q1 2023 May 12, 2023	BUY	$0.7 - $1.41 $147,879 - $297,872	211,257 Added 74.99%	492,975 $369,000
Q4 2022 Feb 13, 2023	SELL	$0.97 - $45.0 $31,282 - $1.45 Million	-32,250 Reduced 10.27%	281,718 $335,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $209,575 - $7.01 Million	171,783 Added 120.82%	313,968 $408,000
Q2 2022 Aug 09, 2022	BUY	$1.15 - $3.34 $34,040 - $98,864	29,600 Added 26.29%	142,185 $227,000
Q1 2022 May 11, 2022	BUY	$2.96 - $7.76 $180,968 - $474,430	61,138 Added 118.84%	112,585 $347,000
Q4 2021 Feb 14, 2022	SELL	$7.4 - $11.66 $29,481 - $46,453	-3,984 Reduced 7.19%	51,447 $381,000
Q3 2021 Nov 12, 2021	BUY	$9.18 - $14.15 $508,856 - $784,348	55,431 New	55,431 $640,000
Q4 2020 Feb 03, 2021	SELL	$5.98 - $12.47 $888,753 - $1.85 Million	-148,621 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$4.65 - $8.73 $597,576 - $1.12 Million	128,511 Added 639.04%	148,621 $916,000
Q2 2020 Aug 11, 2020	BUY	$4.66 - $8.7 $93,712 - $174,957	20,110 New	20,110 $168,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.